MiRNA-embedded ShRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction
Overview
Pharmacology
Authors
Affiliations
RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA polymerase (pol) III promoters has been widely exploited to modulate gene expression in a variety of mammalian cell types. For certain applications, such as lineage-specific knockdown, embedding targeting sequences into pol II-driven microRNA (miRNA) architecture is required. Here, using the potential therapeutic target BCL11A, we demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also increased cytotoxcity in comparison to pol II-driven miRNA adapted shRNAs (shRNA(miR)) in multiple hematopoietic cell lines. We show that the two expression systems yield mature guide strand sequences that differ by a 4 bp shift. This results in alternate seed sequences and consequently influences the efficacy of target gene knockdown. Incorporating a corresponding 4 bp shift into the guide strand of shRNA(miR)s resulted in improved knockdown efficiency of BCL11A. This was associated with a significant de-repression of the hemoglobin target of BCL11A, human γ-globin or the murine homolog Hbb-y. Our results suggest the requirement for optimization of shRNA sequences upon incorporation into a miRNA backbone. These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.
Transcriptional Repressor BCL11A in Erythroid Cells.
Zheng G, Orkin S Adv Exp Med Biol. 2024; 1459:199-215.
PMID: 39017845 DOI: 10.1007/978-3-031-62731-6_9.
Blahetek G, Mayer C, Zuber J, Lenter M, Strobel B Mol Ther Methods Clin Dev. 2024; 32(3):101280.
PMID: 39015407 PMC: 11250862. DOI: 10.1016/j.omtm.2024.101280.
Hart K, Liu B, Brown D, Campo-Fernandez B, Tam K, Orr K Mol Ther Methods Clin Dev. 2024; 32(2):101254.
PMID: 38745893 PMC: 11091523. DOI: 10.1016/j.omtm.2024.101254.
Rajendiran V, Devaraju N, Haddad M, Ravi N, Panigrahi L, Paul J Mol Ther. 2024; 32(3):663-677.
PMID: 38273654 PMC: 10928131. DOI: 10.1016/j.ymthe.2024.01.023.
Koniali L, Flouri C, Kostopoulou M, Papaioannou N, Papasavva P, Naiisseh B Cells. 2023; 12(24).
PMID: 38132168 PMC: 10741507. DOI: 10.3390/cells12242848.